Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- US FDA accepts Cytovation's IND application for Phase II combination studies of CyPep-1, a first-in-class targeted tumor membrane immunotherapyon May 18, 2022 at 11:00 pm
Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that its investigational ...
- SITC's "Targets for Cancer IO: A Deep Dive Series" Offers In-Depth Presentations on Cancer Immunotherapyon May 18, 2022 at 11:00 am
The Society for the Immunotherapy of Cancer (SITC) is offering a nine-part webinar series focused on specific topics within cancer immunotherapy, along with a live, interactive Q&A with renowned ...
- Researchers discover effective combination immunotherapy for liver canceron May 18, 2022 at 10:25 am
Researchers from the University of Missouri School of Medicine have discovered a specific combination immunotherapy that shows promise in the fight against liver cancer.
- Immunotherapy Response in Liver Cancer May Be Predicted by Novel Methodon May 18, 2022 at 5:00 am
Researchers have developed an analytical method that could help predict if an HCC patient would respond to immunotherapy.
- Clinical Trials With Immunotherapy Drugs Are Source Of Hope And Challenges In Treating Aggressive Breast Canceron May 17, 2022 at 11:00 am
Joshalyn Mills had serious side effects from her clinical trial treatments. As a Black woman, Mills believes she wouldn’t have been offered a trial if she ...
- Clinical trials with immunotherapy drugs are source of hope, challenges in treating aggressive breast canceron May 17, 2022 at 5:37 am
Joshalyn Mills of Branford and Nancy Witz of Kensington had the best possible results after being treated in clinical trials with immunotherapy drugs for aggressive breast cancer: Their tumors were ...
- Source of hope and challenges in treating aggressive breast cancer: Connecticut clinical trials with immunotherapy drugson May 17, 2022 at 2:21 am
While there are dramatic successes with immunotherapy drugs, there are also many failures, and researchers are trying to find out why in hopes of expanding the drugs’ effectiveness.
- Immunotherapy drug nivolumab may reduce risk of bladder cancer recurringon May 16, 2022 at 11:00 pm
Immunotherapy with nivolumab (Opdivo) after surgery for metastatic bladder cancer significantly reduces the odds for the tumor's return, a new clinical trial finds.
- Immunotherapy Drug Can Lower Recurrence When Bladder Cancer Spreadson May 16, 2022 at 8:33 am
Immunotherapy with nivolumab (Opdivo) after surgery for metastatic bladder cancer significantly reduces the odds for the tumor's return, a new clinical trial finds. Among 700 patients with urothelial ...
- Immunotherapy combined with chemoradiation and surgery could help treat nonmetastatic gastroesophageal canceron May 16, 2022 at 5:57 am
Immunotherapy has transformed treatment for patients with stage 4 metastatic esophageal and gastric cancers. In patients with these malignancies, immunotherapy has been shown to prolong survival when ...
via Bing News